Trial Profile
Comparing risks of major bleeding and recurrent acute venous thromboembolism (VTE) with apixaban versus warfarin in the treatment of acute venous thromboembolism (VTE)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 May 2019
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Warfarin (Primary) ; Anticoagulants
- Indications Venous thromboembolism
- Focus Therapeutic Use
- 22 May 2019 Results comparing healthcare expenditures between patients receiving outpatient pharmacotherapy with apixaban versus warfarin for VTE in US clinical practice, presented at the 24th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
- 18 Mar 2019 Results presented at the 68th Annual Scientific Session of the American College of Cardiology
- 07 May 2018 New trial record